Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.

Drug delivery systems are widely used to reduce toxicity of drugs and enhance the quality of a patient's life. Nanosomal docetaxel lipid suspension (NDLS) is formulated based on an aqueous lipid delivery system. Patients with breast cancer were not required to be premedicated before administration of NDLS. Docetaxel administered using this delivery system also improves the response rate compared with commercially available docetaxel drug.